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The potential of carbon monoxide to act as a therapeutic agent is now well-established. Controlled
delivery of CO is best achieved using ‘CORMs’: molecules which release known amounts of
carbon monoxide in response to a stimulus. Metal carbonyl complexes will release CO if irradiated
with ultraviolet light, but it is only in the past five years that development of true ‘photoCORMs’ has
been explored. Recent exciting developments in this area now show that design of photoCORMs
operating well into the visible region is achievable. In this Perspective, we examine the growth of
photoCORMs from their origins in the photophysics of metal carbonyls to the latest visible-light
agents.
1 Introduction
The toxic nature of carbon monoxide is well known. As an ex-
cellent pi-acceptor ligand, CO reacts with haemoglobin to form
carboxyhaemoglobin (COHb), reducing the oxygen-carrying ca-
pacity of the blood and thus impairing respiration. This donor
ability is also implicated in other aspects of the dangers of CO:
COHb formation alone cannot fully account for the acute toxicity
seen.1
This same ability to bind strongly to metal centres provides
CO with an additional, beneficial role. Studies on the biological
role of CO have established that it functions as a signalling mo-
lecule,2–5 reminiscent of the discovery that NO plays a similar
role in cell processes.6 Controlled amounts of carbon monoxide
show a positive role in controlling cardiovascular and inflammat-
ory impairment, in promoting wound healing, and bactericidal
action.7–15 Notably, the mode of action of CO in these beneficial
roles is as-yet unresolved. However, that does not prevent exploit-
ation of the positive behaviour of CO in medical applications.
The key challenge in using carbon monoxide as a therapeutic is
that it must be delivered in a strictly-controlled manner. Delivery
of gaseous carbon monoxide is possible but attaining fine control
of volumes is non-trivial. Delivery as a gas is also tied to absorp-
tion by the lungs, limiting the potential for topical or targeted
application. There has therefore been significant effort to pro-
duce molecules which can release CO, so-called CORMs (carbon
monoxide releasing molecules).16–20 The majority of these sys-
tems are based around metal carbonyl fragments, which offer a
direct route to the release of CO. Such organometallic therapeut-
ics are unusual, and efforts have been made to exploit alternative
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CO sources. Non-organometallic systems are in the main limited
by low rates and/or harsh conditions for CO release.1
CORMs may release carbon monoxide in response to a range
of stimuli. Dissolution of many CORM systems in aqueous me-
dia leads to release of CO at physiological temperatures: thermo-
dynamic CORMs. Whilst this provides for the ability to readily
control the amount of CO delivered, it does not allow control of
when and where the CO is released. To do that, triggered CORMs
are required. Enzyme-triggered CORMs (ET-CORMs) make use
of the presence of esterases in cells to bring about CO release at
metal centres.21–24 Triggering using small molecules is also pos-
sible, with the combination of a CORM with a second chemical
agent25–27 allowing temporal control of release. More exotic ap-
proaches have also been explored, for example release triggered
by electromagnetic heating.28
Most CORMs are metal carbonyls, which are well known as
photosensitive systems. An attractive strategy is therefore to trig-
ger release using light: so-called photoCORMs.29 The develop-
ment of photoCORMs has accelerated rapidly over the past dec-
ade. Early work in this area built on known photochemistry of
carbonyl molecules in the hard ultraviolet (UV), moving to mo-
lecules which release on the boundaries of the visible spectrum
and most recently systems which work well under ambient light.
In this Perspective we will trace development of photoCORMs
from the earliest reports to the present day, with a particular focus
on the use of visible light to effect CO release.
2 Ideal behaviours
First and foremost, any putative CORM must release CO in a
clearly-defined way. For a photoCORM this means releasing CO in
response to stimulation by light. It should not release any CO, or
indeed react in any way, until exposed to light, so should be both
water and oxygen tolerant. These conditions are far removed
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Fig. 1 Generalised reactivity of a photoCORM
from the typical organometallic chemistry environment and so
provide a challenging set of requirements. The CORM must react
only when required, not with the surrounding chemical environ-
ment or by enzymatic attack.
Both the photoCORM itself and the breakdown products must
be non-toxic and excretable. For the by-products formed after ac-
tivation, a challenge is that they are likely to be reactive, as at
least one site will have been vacated by CO. Typically, water ad-
ducts are expected to form initially, although this may be followed
by further chemistry (Fig. 1).
To allow delivery as a solution, the photoCORM should be sol-
uble in water or failing that in a mixture of water with dimethyl-
sulfoxide (DMSO). Facilitating this solution may involve modific-
ation of the core molecule architecture with groups to promote
this, such as alcohol functionality.25 Such modification may lead
to an increased mass of the pro-drug, which reduces the overall
active content available.
Whilst the requirement to release CO to constitute a photo-
CORM seems trivial, a more nuanced concern is the nature of the
light required to achieve meaningful activity. Given a light source
emitting far enough into the UV, most carbonyl complexes will
decompose with loss of CO. Many potential photoCORMs rely on
light in the UV to activate, but this is both potentially damaging
to cells and has poor penetration depth into tissue.30,31 Indeed,
the ideal wavelength for issue penetration is in the near infra-red
(IR) region (700 nm to 1100 nm).32
3 Assessing photoCORMs
By definition, a photoCORM must give out carbon monoxide
when exposed to light. As such, any assessment of the activity
of the molecule needs to quantify the CO release and relate this
to the light exposure experienced by the target. Carbon monox-
ide release is typically monitored using the carboxymyoglobin
(COMb) assay.33 As noted earlier, CO binds strongly to metals,
and its reactivity with haemoglobin is at least in part responsible
for its toxicity. The COMb assay exploits this reactivity, with the
irreversible binding of CO to myoglobin (Mb) leading to a clear
change in the visible spectrum (Fig. 2). Monitoring the strong
absorbance at 540 nm can thus be used to quantify CO release,
provided appropriate controls are used.
Separating out the contribution to the UV spectrum of the
photoCORM (and breakdown products) from the Mb/COMb ele-
ments is not without issue.34 Myoglobin is also reactive toward
oxygen, and the dithionite used in the assay may itself react
with CORMs.35 This has driven efforts to develop alternative
assays for (photo)CORMs.17,31 Direct measurement of CO con-
centration is possible by gas chromatography,36 electrochemical
means37 or by using a suitably-designed integrated IR cell.38 Car-
bon monoxide will also react with rhodium complexes39,40 and
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Fig. 3 First photoCORMs reported by Motterlini et al.33
fluorescence precursors.41–44 However, to date it is common to
compare (photo)CORMs based on their performance using the
COMb assay even if one of these alternative methods is also em-
ployed.
Converting rates of CO release into photoreactivity requires
quantification of light input. Typically, this is assessed by calculat-
ing the quantum yield (ΦCO) for CO release at a given wavelength
(λex). This can then be related to the more useful therapeutic
measure, the rate of CO release, by using the intensity of the
light source used, with the necessary correction for the difference
between light given out by the source and that absorbed by the
photoCORM. It is notable that direct comparison of photoCORMs
can be difficult as they have varying λex values and thus different
rates of practical CO release under similar conditions. In particu-
lar, whilst ‘half-life’ values are sometimes given in the literature,
the rate of release of CO is directly dependent on the intensity of
the incident light and the absorption of the solution.
4 Early studies
Studies on the photochemistry of metal carbonyls have a long
history,45 and it is therefore unsurprising that early work in this
area overlaps with more fundamental physical chemistry research
into the nature of the complexes.
The first explicit use of light to trigger release of CO from a
CORM was reported by Motterlini et al. in 2002 (Fig. 3).33 In a
study of the behaviour of simple metal carbonyls as CORMs, 1 and
2 were found to be inert when mixed with water but did release
CO when irradiated with ‘cold light’ over approximately one hour.
These simple metal carbonyls are not amenable to modification,
for example to control light sensitivity or water solubility, so as
platforms for further development were somewhat limited. This
is particularly true for Fe(CO)5, which in addition to low water
solubility is also significantly toxic.
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Fig. 4 First manganese-based photoCORM and functionalised
derivative46,48
5 Ultraviolet photoCORMs
The first system developed specifically to target photoCORM be-
haviour (though before the term was coined) was reported by
Schatzschneider and co-workers (3, Fig. 4).46 This manganese-
based system features a tris(pyrazolyl)methane (tpm) supporting
ligand, leaving three sites on the metal filled by CO. Whilst this
might be expected to allow the complex to deliver three equi-
valents of carbon monoxide, photolysis of 3 at 365 nm yielded
only two photolabile CO molecules per metal centre. Nuernber-
ger and co-workers later established using ultrafast laser spectro-
scopy that only one of the CO groups is liberated from the metal
centre by the primary photochemical step.47
The cationic nature of complex 3 means that it is water-soluble,
and was shown to have efficacy in reducing the viability of cancer
cells.47 Complex 3 was subsequently used in bioimaging applic-
ations,49 although in this context the bound CO molecules were
not released but rather used as markers based on the strong and
distinct C O IR band.
The readily-accessible nature of 3 along with the synthetic
flexibility of the tpm architecture has been exploited by to de-
velop a range of photoCORM systems building upon this. Schatz-
schneider and co-workers functionalised the ‘rear’ of the ligand
with a triple bond, allowing the organometallic part to be coupled
using Sonogashira or ‘click’ chemistry (4).48 The alkyne group
could be successfully reacted to introduce peptide functionality
into the molecule under both of the target reactions without af-
fecting the photoCORM core. Schatzschneider and co-workers
later reported the use of ‘click’ chemistry to bind complex 4 to
the surface of SiO2 particles.
50 The immobilised complex shows
very similar CO release properties to the parent, with qualitative
evidence for photolability at 365 nm.
Work by the Kunz group exploited tripodal nitrogen ligands
featuring a central phosphorus atom (Fig. 5).51 The resulting
complexes have similar structures and CO-release properties to
3, with photolability of between one and two equivalents of CO
at 365 nm.
In 2010, Ford and co-workers reported the tungsten-containing
complex 7 (Fig. 6), at the same time introducing the term ‘pho-
toCORM’. Complex 7 releases CO when irradiated at a number
of wavelengths in the UV (between 305 nm and 405 nm). Exam-
ination of the carbon monoxide release behaviour using a range
P
NRN
RN
NN
NR
P
NH
N
NH
NN
HN
E
5
R = H, Me
6
E = –, O, S
i-Pr
i-Pr i-Pr
Fig. 5 Tripodal nitrogen ligands featuring a phosphorus core51
PAr3
W
CO
CO
COOC
OC SO3
Ar =
7
Fig. 6 Tungsten-based photoCORM reported by Ford and co-workers36
of different detection techniques established that only one equi-
valent of CO is released by photolysis: subsequent degradation
to release further CO equivalents was attributed to the action of
dioxygen on the photoactivated intermediate.
The Kunz group extended the range of tripodal manganese
carbonyls studied by exploiting bis(pyridylmethyl)amine ligands
(Fig. 7). These materials release CO when irritated with a hand-
held UV lamp (365 nm). Complex 9b is a more effective pho-
toCORM than the 9a or 9c; the latter complexes release only
two equivalents of CO while 9b releases all three available COs
when irradiated. The ligand architecture was incorporated into
two related 2-hydroxypropyl methacrylamide copolymer (formed
before addition of the manganese source), using the side chains
in 9b and 9c as linkers to the polymer backbone. These polymer-
bound photoCORMs showed release activity under the myoglobin
assays, although solution turbidity did affect the quantification.34
Several iron-containing metal complexes were examined in
2011 for CO release activity, although not necessarily directly
for use as photoCORMs. In a study focussed on 11C sources for
positron emission tomography, the Long group disclosed the re-
versible CO-release behaviour of complex 10 (Fig. 8).53 Carbon
monoxide is released by this system when irradiated by a high-
pressure mercury lamp operating at 365 nm.
Works and co-workers examined the behaviour of the [FeFe]-
hydrogenase mimic 11 (Fig. 9) when irradiated using flash pho-
tolysis. In accord with related work by Hunt and co-workers,54,55
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Fig. 7 Bis(pyridylmethyl)amine-supported manganese complexes52
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photolysis at UV wavelengths (365 nm) gave signals consistent
with loss of a single CO and formation of a solvato intermediate.
This CO loss is reversible.
The dicationic monocarbonyl 12 (Fig. 10, R = H) is both air
stable and water soluble, and was reported by Kodanko and co-
workers as a rapid CO releaser when irradiated at 365 nm.57 Com-
plete release of the available CO was observed within 10 minutes
of the start of irradiation with a yield of recovered CO of 92 %
from the myoglobin assay. A peptide-bearing derivative was re-
ported (R = Ac-Ala-Gly-OBn) but no quantitative release data was
included.
The cyclopentadienyl-molybdenum complex 13 (Fig. 11) was
reported to release CO but only when irradiated with ‘hard’ UV
light (325 nm).58 This water-soluble complex releases CO slowly
in the dark (indeed, other complexes in the same study were
examined as thermal CORMs by virtue of reaction with wa-
ter alone), but showed significantly enhanced release properties
when irradiated. Myoglobin data showed that at least two equi-
valents of CO were released when the complex was irradiated
with a hand-held lamp.
Berends and Kurz examined the detailed behaviour of com-
plex 3 along with a second related neutral manganese complex 14
(Fig. 12).59 Using a combination of UV, IR and electron paramag-
netic (EPR) spectroscopies, they established that CO loss is a step-
wise process and postulated a mechanism involving formation of
solvato intermediate adducts before oxidation of the metal centre
[Mn(I) to Mn(II)] leads to the formation of Mn O Mn units with
retention of the supporting ligand. Complex 14 is more active in
loss of CO than 3, although this still requires the use of 365 nm UV
illumination.
Mascharak and co-workers also examined cationic tripodal
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Fig. 12 Manganese photoCORM examined in detail by Berends and
Kurz59
manganese complexes related to 3 but featuring one or more
pyridyl rings (Fig. 13).60 Replacement of one pyridyl by a simple
amine donor (15 to 16) and extension of the pi-system (16 to 17)
are both beneficial in terms of the position of UV maxima, moving
from between 240 nm to 260 nm for 15 to 350 nm for 16 and 360 nm
for 17. The latter also shows a greater degree of absorption over
a wider range. Irradiation above 350 nm with a low power light
(120 mW) resulted in quantum yields at 358 nm of around 0.07.
Schatzschneider and co-workers explored the behaviour of
a range of ruthenium-containing structures based around 2,2′-
bypryidine (bpy) ligands (and related structures) (Fig. 14). The
Ru(bpy)n core has been extensively studied,
61 and these systems
are known to exhibit strong MLCT (metal-to-ligand charge trans-
fer) transitions from the metal to low-lying pi∗ orbitals. Com-
plexes 18–20 show strong absorption maxima in the region ap-
prox. 300 nm to 325 nm, with variation in the aromatic architec-
ture (e.g. 18c versus 18d) leading to shifts of the exact position
of the bands. The complexes were largely stable in the absence
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Fig. 13 Tripodal pyridyl-based photoCORMs60
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Fig. 14 Ruthenium bi- and ter-pyridine-based photoCORMs (Boc =
tert-butyloxycarbonyl, Fmoc = 9-fluorenylmethyloxycarbonyl)62
of light (though 18e and 20 did show some decomposition in the
dark in solution) but released up to one equivalent of CO when ir-
radiated at 365 nm. Half-lives for this process ranged between 20
minutes (18c) to 66 minutes (18d). Notably, there was no correl-
ation between the total amount of CO released and the strength
of the UV absorption bands (vide infra). Quantum yield were re-
ported but were described as best taken as a relative measure of
the efficiency of reaction due to the internal shielding effect of
myoglobin in the assays.
Extending their earlier work with symmetrical tripodal man-
ganese systems, Schatzschneider and co-workers have recently
reported a family of complexes based around the tridentate
bis(pyrazoyl)ethylamine core (Fig. 15).44 This architecture has
been chosen to allow derivatization to improve potential delivery
routes. These new structures retained photolability under irradi-
ation at 365 nm with quantum yields of the order of 10−3. Carbon
monoxide release was also reported to occur at 410 nm from com-
plex 22a: the total amount of photolabile CO remained roughly
two equivalents whilst the time taken to release CO was (under
identical conditions) increased by a factor of roughly four.
6 Visible light photoCORMs
As detailed earlier, an ideal photoCORM will release CO when
irradiated in the visible region, with the challenge then be-
ing to find molecules stable in the dark but photoactive in the
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light. Over the past half-decade this challenge has begun to be
addressed. A particularly fruitful avenue has been the design
of complex which facilitate electron transfer from electron-rich
metals to pi∗ orbitals of the ligand via strong metal-to-ligand
charge transfer (MLCT) transitions in the visible/near-IR re-
gion.30 These transfers tend to favour CO release, particularly
at d6 metal centres [Mn(I), Re(I), Fe(II), Ru(II), etc.] where over-
all stability is high. This strategy has been strongly-supported by
computational (density functional theory) calculation, and has re-
cently been reviewed in detail.30
Cleanly delineating the line between a photoCORM active in
the UV and one active in the visible is not straight-forward. Elec-
tronic transitions are broad and may have appreciable extension
from the UV to the visible. Thus molecules with absorption max-
ima in the UV (λ < 400nm) can release CO when irradiated with
visible light. Here, we have taken the division based on the light
used to bring about CO release rather than the absorption max-
ima involved: for practical applications, slow release in the visible
is entirely reasonable even if faster release would be possible in
the UV.
Westerhausen and co-workers examined the CO release proper-
ties of the known complex dicarbonylbis(cysteamine)iron(II) (23,
Fig. 16)63 in 2011.64 Complex 23 was irradiated at 470 nm it re-
leased CO over a period of several minutes. Exposure to broad-
band white light led to rapid release of CO (full release within
minutes). This system was the first to be reported as releasing
CO in the visible region, though the ligand architecture did not
offer obvious handles for further development and modification.
Notably, this system bears no organic chromaphores.
Carbon monoxide release from [FeFe]-hydrogenase mimics has
been extended into the visible region. A system bearing water-
soluble side chains was examined by Fan and co-workers for
CO release at the edge of the visible spectrum.65 Complex 24
(Fig. 17) is water soluble due to the carboxylate groups, and ad-
opts a significantly more ‘open’ geometry than complex 11. Com-
plex 24 releases all of the bound CO under broadband visible
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Fig. 18 Luminescent rhenium-based photoCORM67
irradiation within a few minutes, though detailed data are repor-
ted for irradiation at 390 nm. Complexes similar in structure to 24
have been studied by Liu and co-workers as chemically-triggered
CORMs.25–27
Complexes of the form fac-[Re(bpy)(CO)3(X)]
+ (X = halide)
are well-known as CO oxidation catalysts and luminescence mo-
lecules.66 Ford and co-workers used this known behaviour as
the basis to develop a water-soluble and luminescent photo-
CORM which releases CO at the edge of the visible range.67 By
incorporating a hydroxylated ligand, P(CH2OH)3, into the com-
plex (Fig. 18), Ford was able to solublise the target rhenium sys-
tems in water whilst leaving the overall charge on the system
unchanged. Complex 25 was shown to release one CO when irra-
diated at 405 nm, with a quantum yield of 0.11 (a higher quantum
yield, 0.21, was found at 365 nm). The complex was also strongly
luminescent in aqueous solution, exhibiting a band at 515 nm,
whilst the photoproduct 26 is also active with a band at 585 nm.
These luminescent properties allowed cell uptake of the photo-
CORM to be examined, showing that cells remain viable in the
presence of this system. The luminescent properties of both the
photoCORM and breakdown product allowed qualitative demon-
stration of CO release in cells, with the shift of emission detectable
in vitro.
As in the UV, systems based around supporting manganese
tricarbonyl cores have been widely used as visible-light photo-
CORMs. Smith and co-workers have exploited the bypyridyl lig-
and bound to manganese to develop dendritic photoCORMs.68
These systems were prepared in two dendrimer generations, bear-
ing four and eight metal centres, respectively. Both showed sta-
bility in the dark with CO release at 410 nm and comparable total
CO quantities available. The dendritic systems and a monometal-
lic model 28 showed appreciable extinction coefficients in the vis-
ible, ε410 = 3527M−1 cm−1 for the latter. As would be expected,
this value scaled roughly with the total metal complex loading.
Release of CO at 410 nm was found to take around twice as long
for the dendrimer as for the monomeric system under otherwise
identical conditions. Quantum yields for all three was similar at
approx. 3×10−3: as with other values from myoglobin assay con-
ditions, this may be suppressed by the presence of the protein
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complex.
Zobi et al. have supported the fac-Mn(CO)3 fragment using
a tetra-azacyclotetradecane ligand (Fig. 20).69 Complex 29 fea-
tures a vitamin B12-derived side-chain which confers water solu-
bility and cellular targeting whilst being remote from the pho-
toCORM centre. Whilst 29 shows an absorption maximum at
388 nm, irradiation at 470 nm (blue LED source) gave CO release
over a period of around three hours. Illumination using a green
Ar laser (several discrete bands in the 450 nm to 550 nm range)
also gave CO release though at a reduced rate. Experiments un-
der limiting conditions showed that all three equivalents of CO
were released from the photoCORM during irradiation, though
no intermediates were observed. Cellular uptake of the photo-
CORM and a protective effect of light-activated CO release under
conditions of hypoxia was demonstrated.
Bengali and co-workers used a di-imine ligand in the construc-
tion of fac complexes (Fig. 21), giving a system with an absorp-
tion maximum as 582 nm.70 This system exhibits CO release at
560 nm as indicated by IR spectroscopy of the complex itself. The
photolability of the Mn CO bond was assigned to a metal-ligand
charge-transfer (MLCT) band to the di-imine pi∗ orbitals from a
combination of the Mn CO pi orbital the bromide p orbital. This
change would be expected to disrupt back-bonding from CO to
the metal and thus promote ligand loss. This analysis was sup-
ported by time-dependent density function theory (TD-DFT) cal-
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culations.
Conversion of the neutral system to a series of cationic com-
plex (31, L = CO, THF, MeCN) could be achieved using a halide
abstractor. These systems lack the halide p orbital present in 30,
displacing the absorption maximum to 420 nm and significantly
increasing light stability. For example, in the case L = CO, the
time required for CO release is raised by around six times under
identical conditions.
The most significant contribution to date to the development
of visible light photoCORMs has been made by the Mascharak
group.30 Their approach has been focussed on a fac-Mn(CO)3
core featuring a bidentate (or potentially tridentate) nitrogen
ligand and one additional supporting ligand (typically Br– or
PPh3) (Fig. 22). In this approach, the ability of the CO to dis-
sociate is increased by providing low-lying orbitals on the ligand
system. This then allows electron density to transfer from the
M CO bonding orbitals on photo-activation and thus enhances
photolability.
Following early work with release primarily in the UV,60 this
approach was followed making use of both bidentate and po-
tentially tridentate Schiff base ligand architectures (Fig. 23).71
When complexed to the target manganese core, only two donors
(highlighted in blue) bind to the metal, with the third re-
maining uncoordinated. These systems show significant ab-
sorptions in the visible, with the sulfur-containing ligand 34
giving the most desirable outcome. Notably, there was a
marked difference between complexes bearing halide ligands
and those featuring other donors: fac-Mn(34)(CO)3Br as an
absorbption maximum of 535 nm which is shifted to 435 nm in
fac-[Mn(34)(CO)3(MeCN)][ClO4]. Illumination with low power
(5 mW) visible light (broad band with a 400 nm cutoff) led to CO
release with quantum yields in the range 0.12 to 0.37 at 509 nm.
The complex fac-[Mn(32)(CO)3(MeCN)][ClO4] was later suppor-
ted electrostatically on mesoporous Al-MCM-41 nanoparticles,72
where broadband illumination leads to the anticipated CO re-
lease.
Ligand 34 was later reacted with ruthenium to give a series
of complexes featuring a meridional architecture (Fig. 24):73 in
contrast to manganese, all three donor atoms bind to ruthenium.
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Both 36 and 37 release CO when illuminated in the UV (30 mW,
300 nm to 350 nm), but only 37 does so in visible light. The rate
of CO release is dependent on wavelength: kCO for 37 is 0.031(1)
with light cut off at 380 nm but only 0.0032(1) when the filter is
at 440 nm. Thus the best CO release behaviour is seen with the
fewest CO ligands, a consequence of the need to control MLCT
bands.
Building on this work, Mascharak described the behaviour
of fac-Mn(CO)3 supported by bidentate ligands 38 and 39
(Fig. 25).74,75 These systems offer good CO release behaviour
in the visible, with fac-[Mn(38)(CO)3Br] showing an absorption
maximum at 586 nm, and a rate for CO release of 5 min−1 when ir-
radiated with broadband light (cutoff 520 nm). Carbon monoxide
release from fac-[Mn(39)(CO)3Br] can be traced in vitro by fluor-
escence measurement and was shown to lead to cell apoptosis.
The comparison between Mn and Re complexes of ligand 38
was used to explore the detailed requirements for CO release.76
Whilst both complexes of formula fac-M(38)(CO)3Br (M = Mn,
Re) have absorption maxima between 500 nm and 600 nm, only
the manganese complex is effective as a visible light photoCORM.
Similar results were obtained for fac-[M(38)(CO)3(PPh3)][ClO4]
(though here there is greater difference in the λmax values). This
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Fig. 25 Bidentate N,N-ligands for fac-Mn(CO)3 photoCORMs
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Fig. 27 PhotoCORM for use with a nanoparticle up-converter system.78
experimental data was combined with TD-DFT results to show
that UV-visible spectra alone are not predictive of good CO re-
lease: it is the nature of the absorbing orbitals which is important,
as energy must be transferred to CO-bond cleavage.
Most recently, this work has been extended to the ligands 40
and 41 (Fig. 26).77 These more extended pi-systems lead to fac-
Mn(L)(CO)3Br complexes with strong bands well into the visible
(above 550 nm) and which are light sensitive in the solid state un-
der ambient light. Complex fac-Mn(40)(CO)3Br is currently the
lead example of a visible light photoCORM, with a quantum yield
of 0.7(2) at 545 nm. The rate of CO release from these systems is
also very high, with complete CO release achieved in seconds.
Complementing this approach of ligand-based tuning, Ford and
co-workers have recently reported an approach making use of
nanoparticle up-converters to enhance CO release.78 Complex 42
(Fig. 27) will release roughly two equivalents of CO when ir-
radiated at 470 nm. This complex could then be entrapped in
a a phospholipid-functionalised poly(ethylene glycol) layer sur-
rounding lanthanide ion doped upconversion nanoparticles. The
polymer renders the ensemble water-soluble whilst the nano-
particle system will allow useful CO release using infra-red light.
Irradiation of the combined photoCORM/nanoparticle construct
at 980 nm resulted in CO release mirroring that seen when using
UV light (365 nm). This approach thus offers the opportunity to
create very sensitive release systems by bypassing elaborate lig-
and/complex design and synthesis.
7 Metal-free photoCORMs
Whilst most photoCORMs are based around metal carbonyl com-
plexes, a small number of systems have been reported which do
not feature a metal centre . Klán and co-workers have reported a
system based on the fluorescein analogue 43 (Fig. 28).79 The be-
O O
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R
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Fig. 28 Metal-free photoCORMs (R = H, (OC2H4)2OMe, OC8H17)
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81
haviour of this system is pH-dependent, with the compound giv-
ing off CO under visible irradiation (500 nm) in phosphate buffer
(pH = 7.4) with a small quantum yield, 7(3)×10−4. Under neut-
ral and acidic conditions the photoproduct could be identified as
44. Published almost at the same time, Liao and co-workers de-
scribed CO release from the anthracene derivative 45 (Fig. 28).80
This material is formed via Diels–Alder chemistry, and then un-
dergoes a known photoreaction to release two equivalents of CO
under irradiation at 470 nm. To prevent hydration of the diketone
unit interfering in this process, the molecules were encapsulated
in hydrophobic micelle structures.
Very recently, Berreau and co-workers have reported the light-
driven release of CO from a series of compounds related to 47
(Fig. 29).81 Carbon monoxide is released by this system when
irradiated at 419 nm in the presence of oxygen, which labelling
studies demonstrated is incorporated into the photoproduct. By
adjusting the framework to give 49, CO release could be affected
using light with wavelength >546 nm.
8 Biological testing
Whilst testing photoCORM systems for CO release is well under-
stood in terms of myoglobin assay and quantum yield measure-
8 | 1–11
ments, there has been much less attention paid to testing the same
systems in vitro.
Testing for cytotoxicity is the most widely examined criterion,
with cell viability assessed either in presence or absence of light in
a number of reports.65,67,75,80 Whilst these studies show that the
compounds tests are not toxic, the potential of photoCORMs in
active toxicity toward cancer cells has also been considered.46,74
The latter studies focus on the possible ‘turn on’ of activity when
irradiated.
Beyond toxicity, there are a small number of examples of
testing for other biological effects. Mascharack and co-workers
have tested for vascular dilatation in rat aorta cells,60,72 whilst
Quaroni and co-workers have shown a protective effect in hypoxia
conditions.69 Activation of Ca2+ potassium channels expressed
has been demonstrated by Westerhausen and co-workers.64 Not-
ably, whilst anti-inflammatory effects are known for CO, and have
been demonstrated in other CORMs,82 to date there are no re-
ports of photoCORMs showing this activity in whole-cell assays.
9 Summary and outlook
Developments in photoCORMs has progressed rapidly in the past
decade. Early structures based around simple metal carbonyls
have been supplanted by more sophisticated approaches in which
manipulation of MLCT bands allows tuning the photosensitivity
well into the visible range.30 Achieving CO release with visible
light in combination with stable, water-soluble materials is begin-
ning to be realised, but we are only now mapping out the key
requirements for this chemistry to be achieved. New systems are
likely to address both the fundamental and practical challenges
that remain in the coming years, particularly in combination with
biomaterials for intracellular delivery.83
Whilst the underlying chemistry is now becoming better-
understood, it is clear that for application more attention must
begin to be focussed on charactering the performance of putat-
ive photoCORMs in vitro. Currently, data on the cytotoxicity of
the new materials is sparse, with activity in for example anti-
inflammatory assays thus-far unreported. Understanding the be-
haviours of the new systems in these real-world tests is vital.
New visible-light photoCORMs pose their own questions: just
how much light sensitivity is ‘best’? By expanding the range of
molecules available such that we can now being to test this, cur-
rent developments are pathing the way to examine this question.
It can only be fully understood outside of the laboratory context:
the complexities of real use cases are often a long way from the
idealised conditions of the academic laboratory.
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